Академический Документы
Профессиональный Документы
Культура Документы
BSE: 500124
NYSE: RDY
Group #4
Hemant Pandey – WMP13017
Himanshu Jaiswal – WMP13018
Himanshu Sawhney – WMP13019
Hirdesh Kumar – WMP13020
Ina Thakral – WMP13021
Jagrit Sharma – WMP13022
Vision and Mission Statements
Vision
To become one of the leading global generics companies providing tough-
to-make and truly differentiated products that address unmet needs of
patients globally
Mission
The mission is to improve the quality of life and life expectancy itself. This
requires good science. But for science to be good, it has to result in
affordable medicine.
Does the firm have competitive
advantage?
• Company has been outperforming industry average on profitability Sources of Competitiveness
• R&D capabilities within
Generics
• State-of-the-art technology in
• Company is making economic profit
cell line and process
development
• Research capabilities within
Biologics
Is the firm Diversified?
Internal Assessment
Technology Strategy
• Generics - Generic Drugs are low cost
reinforced versions of actual patented drugs.
Here, the core concept, basic mix and linkages
are not changed.
• Cost of error can be huge and can not be reversed (few times) • Increasing industry growth of Biologics: 14 times higher than Chemical drugs
• Alignment with Mission Statement: Affordable medicine, Increasing quality of life and
life expectancy
Few Facts: